<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697823</url>
  </required_header>
  <id_info>
    <org_study_id>S64387</org_study_id>
    <nct_id>NCT04697823</nct_id>
  </id_info>
  <brief_title>Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate.</brief_title>
  <acronym>TETHER</acronym>
  <official_title>Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate: a Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing whether the use of hyaluronan-enriched transfer medium can increase the cumulative&#xD;
      ongoing pregnancy rate&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>number of transfers needed to reach ongoing pregnancy</measure>
    <time_frame>ongoing defined as a pregancy with a viable fetus with FHB at 12 weeks of pregnancy</time_frame>
    <description>The primary outcome parameter is the number of transfers needed to reach ongoing pregnancy (ongoing defined as a pregancy with a viable fetus with FHB at 12 weeks of pregnancy), as a time-to-event outcome variable. Patients that do not reach pregnancy, are censored at their last transfer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of transfers needed to reach clinical pregnancy, life birth, miscarriage, multiple pregnancy</measure>
    <time_frame>until Live birth: 9 months after ET</time_frame>
    <description>clinical pregnancy is defined as a pregnancy with at least one intrauterine (IU) or extrauterine (EU) fetal sac at 6-7 weeks of pregnancy)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hyaluronan-EnRiched Medium</condition>
  <condition>Randomized Controlled Trial</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving an embryo transfer in hyaluronan-enriched transfer medium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receiving an embryo transfer in conventional culture medium</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>use of hyaluronan-enriched transfer medium</intervention_name>
    <description>In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with own oocytes/embryos;&#xD;
&#xD;
          -  Patients with female age at 1st OR in the study &lt;40 year;&#xD;
&#xD;
          -  Patients planned for a 2nd oocyte retrieval, with no clinical ongoing pregnancy after&#xD;
             the previous oocyte retrieval&#xD;
&#xD;
          -  Patients planned for a 3rd oocyte retrieval with no clinical ongoing pregnancy after&#xD;
             previous oocyte retrievals&#xD;
&#xD;
          -  Patients with female age at 1st OR in the study &lt;40 year;&#xD;
&#xD;
          -  Patients with BMI â‰¤32;&#xD;
&#xD;
          -  Patients with written informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Debrock, PhD</last_name>
    <phone>0032016340812</phone>
    <email>sophie.debrock@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leuven University Fertility Center</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Debrock, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Sophie Debrock</investigator_full_name>
    <investigator_title>clinical embryologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

